Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

EMBLAVEO

AVIBACTAM SODIUM; AZTREONAM

Standard Dose
EQ 0.5GM BASE/VIAL;1.5GM/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview EMBLAVEO is listed in Drugs@FDA under application 217906 (NDA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient AVIBACTAM SODIUM; AZTREONAM Form and strength POWDER;INTRAVENOUS - EQ 0.5GM BASE/VIAL;1.5GM/VIAL Sponsor ABBVIE Submission history Latest submission status date: 2025-02-07 00:00:00.

Structured Monograph

Clinical summary

Approval overview EMBLAVEO is listed in Drugs@FDA under application 217906 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient AVIBACTAM SODIUM; AZTREONAM Form and strength POWDER;INTRAVENOUS - EQ 0.5GM BASE/VIAL;1.5GM/VIAL Sponsor ABBVIE Submission history Latest submission status date: 2025-02-07 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.